CM 336
Alternative Names: CM-336; OM-336Latest Information Update: 24 Jun 2025
At a glance
- Originator KeyMed Biosciences
- Developer KeyMed Biosciences; Ouro Medicines
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Bullous pemphigoid; Multiple myeloma
- Phase I Idiopathic thrombocytopenic purpura
- Clinical Phase Unknown Autoimmune haemolytic anaemia
Most Recent Events
- 13 Jun 2025 Clinical trials in Autoimmune haemolytic anaemia (SC)
- 13 Jun 2025 National Medical Products Administration approves IND application for CM 336 for phase-II trial in Amyloid light-chain amyloidosis in China
- 12 Jun 2025 Ouro Medicines plans a clinical trial for Haemolytic anaemia and Thrombocytopenic purpura in the second half of 2025